List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Randomized Prospective Phase II Clinical Trial of NVX in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme GBM is a malignant primary brain tumor affecting about new cases per year in the U S Average survival is only about months Radiation RT is most commonly administered as fractions of Gray each over weeks with concomitant temozolomide TMZ GBM tumors are hypoxic The primary mechanism of RT is creation of singlet oxygen hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated Microarray Printing and Detection System

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

    SBIR Phase II 2017 Department of Health and Human Services
  3. GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

    SBC: PAPGENE, INC.            Topic: NCI

    This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Yeast based Immunotherapy against Clostridium difficile Infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of Natural Products and Derivatives as Antimalarial Agents

    SBC: Cascade Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY The proposed research focuses on the development of novel therapeutic agents for the treatment of malaria caused by P falciparum Preliminary studies have discovered some novel natural products and derivative molecules with potent in vitro activity against both sensitive and multidrug resistant malaria strains including the newly emerging artemisinin resistant parasite line New ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Strategies to Improve Production of a Full Length Native HIV Env Spike

    SBC: CODEX BIOSOLUTIONS            Topic: R

    Project Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Serotype independent therapeutic vaccine for Streptococcus pneumoniae

    SBC: Integrated Biotherapeutics, Inc.            Topic: R

    In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...

    SBIR Phase I 2017 Department of Health and Human Services
  8. Enhancing cytarabine efficacy in leukemia through CDK inhibition

    SBC: SENEX BIOTECHNOLOGY, INC.            Topic: 102

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: NCI

    Radiopharmaceutical therapyRPTis an emerging cancer treatment that delivers radiation directly to cancer cellsThe recent FDA approval ofRa Xofigotmfor resistant metastatic prostate cancer and its commercial success provides an example of the therapeutic and commercial potential of this modalityIn additiondrug companies have large libraries of targets and targeting moleculesProgress in chelators an ...

    SBIR Phase I 2017 Department of Health and Human Services
  10. Novel injectable resiquimod formulation for treatment of metastatic cancers

    SBC: Curebiotech, Inc.            Topic: NCI

    PROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government